Floatz logo

Turalio

Leukemia, Promyelocytic, Acute

National Cancer Institute (NCI)Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Leukemia, Promyelocytic, Acute cohort.

Asset / SponsorPhaseRating
Vesanoid
The Affiliated People's Hospital of Ningbo University
Phase 4A
Cytosin-Arabinosid
Associazione Italiana Ematologia Oncologia Pediatrica
Phase 4A
Idarubicine
Technische Universität Dresden
Phase 4A
Arsenic Trioxide
Quetzal Therapeutics
Phase 4BBB
Mitoxantrone
Technische Universität Dresden
Phase 4BBB

View all 50 →

Same molecule, other indications

Turalio is also rated in:

precursor lymphoblastic lymphoma/leukemiaDormant
CC
Indicative ·
41 / 100
View asset →
sarcomaDormant
C
Indicative ·
39 / 100
View asset →
plexiform neurofibromaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →